Please use this identifier to cite or link to this item: 192.168.6.56/handle/123456789/3111
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBorn, G.V.R.-
dc.date.accessioned2018-09-20T08:43:47Z-
dc.date.available2018-09-20T08:43:47Z-
dc.date.issued2002-
dc.identifier.isbn978-3-642-78434-7-
dc.identifier.urihttp://10.6.20.12:80/handle/123456789/3111-
dc.descriptionIt has been almost 20 years since the discovery by Kohler and Milstein of the technology to produce monoclonal antibodies (MAbs), a discovery that promised revolutionary changes in research, clinical diagnosis and human therapy. From today's perspective, it is fair to conclude that this promise has been realized in two areas of the three. As research tools, MAbs have been invaluable: their ability to selectively bind and localize specific antigens, detect and identify new ligands and their receptors, and agonize and/or antagonize specific molecular interactions continues to provide a useful and enabling technology to basic research endeavors. Similarly,en
dc.languageenen
dc.language.isoenen_US
dc.publisherspringeren_US
dc.subjectpaharmacologyen_US
dc.titleHandbook of experimental pharmacologyen_US
dc.typeBooken_US
Appears in Collections:Veterinary Medicine

Files in This Item:
File Description SizeFormat 
50.pdf.pdf26.86 MBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.